LMR Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

LMR Partners’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	+2,032	New	+$1.04M	﹤0.01%	1036
2025 Q3	–	Sell	-1,242	Closed	-$376K	–	1578
2025 Q2	$376K	Hold	1,242	–	–	﹤0.01%	1009
2025 Q1	$411K	Buy	+1,242	New	+$408K	﹤0.01%	952
2024 Q2	–	Sell	-22,108	Closed	-$5.26M	–	1225
2024 Q1	$5.9M	Sell	22,108 -29,777	-57%	-$7.02M	0.06%	281
2023 Q4	$12M	Buy	51,885 +44,385	+592%	+$7.77M	0.14%	178
2023 Q3	$1.1M	Buy	+7,500	New	+$1.41M	0.01%	466
2021 Q1	–	Sell	-3,130	Closed	-$348K	–	1019
2020 Q4	$348K	Buy	+3,130	New	+$383K	0.01%	379
2016 Q3	–	Sell	-3,258	Closed	-$30K	–	424
2016 Q2	$30K	Buy	+3,258	New	+$39.1K	﹤0.01%	461

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LMR Partners's MDGL Position: Q2 2026 in Review

LMR Partners opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 2,032 shares worth $1.09M. The stake represents ﹤0.01% of the portfolio and ranks #1036 among its holdings. This is a return to the name: LMR Partners previously reported a position in MDGL as recently as Q2 2025.

LMR Partners first reported a position in MDGL in Q2 2016 and has held it in 8 quarters since. The position peaked at $12M in Q4 2023. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

LMR Partners held 2,032 shares of Madrigal Pharmaceuticals worth $1.09M as of Q2 2026.
Madrigal Pharmaceuticals was a new LMR Partners position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of LMR Partners's portfolio in Q2 2026, its #1036 holding.
LMR Partners first reported a position in Madrigal Pharmaceuticals in Q2 2016 and has held it in 8 quarters since.
LMR Partners's Madrigal Pharmaceuticals position peaked at $12M in Q4 2023.
414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.